Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. Eriksson C, Soderling J, Karlqvist S, Broms G, et al. Dig Dis Sci 2023 Mar 17. doi: 10.1007/s10620-023-07897.

Read + Share

Amedeo Smart

Independent Medical Education

Eriksson C, Soderling J, Karlqvist S, Broms G, et al. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. Dig Dis Sci 2023 Mar 17. doi: 10.1007/s10620-023-07897.
PMID: 36929241